Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
Más filtros










Intervalo de año de publicación
1.
Front Immunol ; 14: 1294766, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38077314

RESUMEN

Type I interferonopathies are a heterogenic group of rare diseases associated with an increase in type I interferon (IFN). The main challenge for the study of Type I interferonopathies is the lack of a well-founded animal model to better characterize the phenotype as well as to perform fast and large drug screenings to offer the best treatment options. In this study, we report the development of a transgenic zebrafish model of Type I interferonopathy overexpressing ifih1 carrying the mutation p.Arg742His (Tg(ifih1_mut)), corresponding to the human mutation p.Arg779His. RNA sequence analysis from Tg(ifih1_mut) larvae revealed a systemic inflammation and IFN signature upon a suboptimal poly I:C induction compared with wild-type larvae, confirming the phenotype observed in patients suffering from Type I interferonopathies. More interestingly, the phenotype was manifested in the zebrafish inflammation and Type I IFN reporters nfkb:eGFP and isg15:eGFP, respectively, making this zebrafish model suitable for future high-throughput chemical screening (HTS). Using the unique advantages of the zebrafish model for gene editing, we have generated Tg(ifih1_mut) knocked down for mavs and ikbke, which completely abrogated the Poly I:C induction and activation of the GFP of the reporters. Finally, we used an FDA-approved drug, Baricitinib (Jak1/Jak2 inhibitor), which was able to reduce the inflammation and the ISG expression. Our results demonstrate the potential of this model to further understand AGS pathological mechanisms and to identify novel therapeutic drugs by HTS.


Asunto(s)
Interferón Tipo I , Pez Cebra , Animales , Humanos , Inflamación/genética , Interferón Tipo I/genética , Poli I , Pez Cebra/genética , Helicasa Inducida por Interferón IFIH1
2.
Int J Mol Sci ; 24(9)2023 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-37175698

RESUMEN

Atopic dermatitis (AD) is a chronic inflammatory skin disease of very high prevalence, especially in childhood, with no specific treatment or cure. As its pathogenesis is complex, multifactorial and not fully understood, further research is needed to increase knowledge and develop new targeted therapies. We have recently demonstrated the critical role of NAD+ and poly (ADP-ribose) (PAR) metabolism in oxidative stress and skin inflammation. Specifically, we found that hyperactivation of PARP1 in response to DNA damage induced by reactive oxygen species, and fueled by NAMPT-derived NAD+, mediated inflammation through parthanatos cell death in zebrafish and human organotypic 3D skin models of psoriasis. Furthermore, the aberrant induction of NAMPT and PARP activity was observed in the lesional skin of psoriasis patients, supporting the role of these signaling pathways in psoriasis and pointing to NAMPT and PARP1 as potential novel therapeutic targets in treating skin inflammatory disorders. In the present work, we report, for the first time, altered NAD+ and PAR metabolism in the skin of AD patients and a strong correlation between NAMPT and PARP1 expression and the lesional status of AD. Furthermore, using a human 3D organotypic skin model of AD, we demonstrate that the pharmacological inhibition of NAMPT and PARP reduces pathology-associated biomarkers. These results help to understand the complexity of AD and reveal new potential treatments for AD patients.


Asunto(s)
Dermatitis Atópica , Psoriasis , Animales , Humanos , Inflamación , NAD/metabolismo , Poli(ADP-Ribosa) Polimerasa-1/metabolismo , Poli Adenosina Difosfato Ribosa/metabolismo , Poli ADP Ribosilación , Inhibidores de Poli(ADP-Ribosa) Polimerasas/farmacología , Psoriasis/etiología , Pez Cebra/metabolismo
3.
Int J Mol Sci ; 23(17)2022 Aug 23.
Artículo en Inglés | MEDLINE | ID: mdl-36076906

RESUMEN

A retrospective study of 200 psoriasis patients and 100 healthy donors in a Spanish cohort was carried out to study the comorbidities associated with psoriasis and their association with the response to phototherapy. The results showed a higher incidence of psychiatric disease, liver disease, kidney disease, hypertension, heart disease, vascular disease, diabetes, gastrointestinal disease, autoimmune and infectious diseases, dyslipidemia, and psoriatic arthritis in patients with psoriasis than in the control group. The incidence of comorbidities was higher in psoriasis patients over 40 years old than in the control individuals of the same age, which could be indicative of premature aging. Phototherapy was seen to be an effective treatment in cases of moderate-severe psoriasis, total whitening being achieved in more than 30% of patients, with women showing a better response than men. Narrow-band ultraviolet B was found to be the most effective type of phototherapy, although achievement of PASI100 was lower in patients with liver disease, hypertension, heart disease, vascular disease, or diabetes. Strikingly, liver disease and anemia comorbidities favored therapeutic failure. Finally, zebrafish and human 3D organotypic models of psoriasis point to the therapeutic benefit of inhibiting the glucose transporter GLUT1 and the major regulator of blood glucose dipeptidyl peptidase 4. Our study reveals that specific comorbidities of psoriasis patients are associated to failure of phototherapy and, therefore, need to be considered when planning treatment for these patients.


Asunto(s)
Hipertensión , Psoriasis , Terapia Ultravioleta , Adulto , Animales , Femenino , Humanos , Masculino , Fototerapia/métodos , Psoriasis/tratamiento farmacológico , Psoriasis/terapia , Estudios Retrospectivos , Terapia Ultravioleta/métodos , Pez Cebra
5.
PLoS Biol ; 19(11): e3001455, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34748530

RESUMEN

Several studies have revealed a correlation between chronic inflammation and nicotinamide adenine dinucleotide (NAD+) metabolism, but the precise mechanism involved is unknown. Here, we report that the genetic and pharmacological inhibition of nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enzyme in the salvage pathway of NAD+ biosynthesis, reduced oxidative stress, inflammation, and keratinocyte DNA damage, hyperproliferation, and cell death in zebrafish models of chronic skin inflammation, while all these effects were reversed by NAD+ supplementation. Similarly, genetic and pharmacological inhibition of poly(ADP-ribose) (PAR) polymerase 1 (Parp1), overexpression of PAR glycohydrolase, inhibition of apoptosis-inducing factor 1, inhibition of NADPH oxidases, and reactive oxygen species (ROS) scavenging all phenocopied the effects of Nampt inhibition. Pharmacological inhibition of NADPH oxidases/NAMPT/PARP/AIFM1 axis decreased the expression of pathology-associated genes in human organotypic 3D skin models of psoriasis. Consistently, an aberrant induction of NAMPT and PARP activity, together with AIFM1 nuclear translocation, was observed in lesional skin from psoriasis patients. In conclusion, hyperactivation of PARP1 in response to ROS-induced DNA damage, fueled by NAMPT-derived NAD+, mediates skin inflammation through parthanatos cell death.


Asunto(s)
Inflamación/patología , NAD/metabolismo , Nicotinamida Fosforribosiltransferasa/metabolismo , Parthanatos , Poli(ADP-Ribosa) Polimerasas/metabolismo , Piel/patología , Animales , Factor Inductor de la Apoptosis/metabolismo , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Proliferación Celular/efectos de los fármacos , Daño del ADN , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/efectos de los fármacos , Inflamación/genética , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Queratinocitos/patología , Larva/metabolismo , NADPH Oxidasas/antagonistas & inhibidores , NADPH Oxidasas/metabolismo , Nicotinamida Fosforribosiltransferasa/antagonistas & inhibidores , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Parthanatos/efectos de los fármacos , Parthanatos/genética , Poli Adenosina Difosfato Ribosa/metabolismo , Inhibidores de Poli(ADP-Ribosa) Polimerasas/farmacología , Proteínas Inhibidoras de Proteinasas Secretoras/deficiencia , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , Psoriasis/genética , Psoriasis/patología , Especies Reactivas de Oxígeno/metabolismo , Pez Cebra , Proteínas de Pez Cebra/deficiencia , Proteínas de Pez Cebra/metabolismo
7.
Dev Comp Immunol ; 115: 103881, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33038343

RESUMEN

Nicotinamide adenine dinucleotide (NAD+) is the most important hydrogen carrier in cell redox reactions. It is involved in mitochondrial function and metabolism, circadian rhythm, the immune response and inflammation, DNA repair, cell division, protein-protein signaling, chromatin remodeling and epigenetics. Recently, NAD+ has been recognized as the molecule of life, since, by increasing NAD+ levels in old or sick animals, it is possible to improve their health and lengthen their lifespan. In this review, we summarize the contribution of NAD+ metabolism to inflammation, with special emphasis in the major NAD+ biosynthetic enzyme, nicotinamide phosphoribosyl transferase (NAMPT), and the NAD+-consuming enzyme, poly(ADP-ribose) polymerase (PARP). The extracurricular roles of these enzymes, i.e. the proinflammatory role of NAMPT after its release, and the ability of PARP to promote a novel form of cell death, known as parthanatos, upon hyperactivation are revised and discussed in the context of several chronic inflammatory diseases.


Asunto(s)
Inflamación/inmunología , Nicotinamida Fosforribosiltransferasa/metabolismo , Parthanatos/inmunología , Poli(ADP-Ribosa) Polimerasas/metabolismo , Animales , Enfermedad Crónica , Modelos Animales de Enfermedad , Humanos , Inflamación/tratamiento farmacológico , NAD/metabolismo , Nicotinamida Fosforribosiltransferasa/antagonistas & inhibidores , Inhibidores de Poli(ADP-Ribosa) Polimerasas/farmacología , Inhibidores de Poli(ADP-Ribosa) Polimerasas/uso terapéutico , Transducción de Señal/inmunología
11.
Dev Comp Immunol ; 108: 103666, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32126244

RESUMEN

Psoriasis is a skin inflammatory disorder that affects 3% of the human population. Although several therapies based on the neutralization of proinflammatory cytokines have been used with relative success, additional treatments are required. The in silico analysis of gene expression data of psoriasis lesional skin and an analysis of vitamin B6 metabolites in the sera of psoriasis patients point to altered vitamin B6 metabolism at both local and systemic levels. Functional studies showed that vitamin B6 vitamers reduced skin neutrophil infiltration, oxidative stress and Nfkb activity in two zebrafish models of skin inflammation. Strikingly, inhibition of glycogen phosphorylase L (Pygl) and glucose-6-phosphate dehydrogenase (G6pd), two vitamin B6-regulated enzymes, alleviated oxidative-stress induced inflammation in zebrafish skin inflammation models. Despite the central role of G6pd in antioxidant defenses, the results of the study demonstrate that glycogen stores and G6pd fuel NADPH oxidase to promote skin inflammation, revealing novel targets for the treatment of skin inflammatory disorders.


Asunto(s)
Glucosafosfato Deshidrogenasa/metabolismo , Glucógeno Fosforilasa de Forma Hepática/metabolismo , Psoriasis/inmunología , Vitamina B 6/metabolismo , Proteínas de Pez Cebra/metabolismo , Animales , Animales Modificados Genéticamente , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Biopsia , Conjuntos de Datos como Asunto , Modelos Animales de Enfermedad , Perfilación de la Expresión Génica , Glucosafosfato Deshidrogenasa/antagonistas & inhibidores , Glucosafosfato Deshidrogenasa/genética , Glucógeno/metabolismo , Glucógeno Fosforilasa de Forma Hepática/antagonistas & inhibidores , Glucógeno Fosforilasa de Forma Hepática/genética , Células HaCaT , Humanos , Microscopía Intravital , NADPH Oxidasas/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/inmunología , Psoriasis/sangre , Psoriasis/tratamiento farmacológico , Psoriasis/patología , Transducción de Señal/efectos de los fármacos , Transducción de Señal/inmunología , Piel/diagnóstico por imagen , Piel/efectos de los fármacos , Piel/inmunología , Piel/patología , Vitamina B 6/sangre , Pez Cebra
12.
Dev Comp Immunol ; 105: 103583, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31862296

RESUMEN

The zebrafish has become an excellent model for the study of inflammation and immunity. Its unique advantages for in vivo imaging and gene and drug screening have allowed the visualization of dual oxidase 1 (Duox1)-derived hydrogen peroxide (H2O2) tissue gradients and its crosstalk with neutrophil infiltration to inflamed tissue. Thus, it has been shown that H2O2 directly recruits neutrophils via the Src-family tyrosine kinase Lyn and indirectly by the activation of several signaling pathways involved in inflammation, such as nuclear factor κB (NF-κB), mitogen activated kinases and the transcription factor AP1. In addition, this model has also unmasked the unexpected ability of H2O2 to induce the expression of the gene encoding the key neutrophil chemoattractant CXC chemokine ligand 8 by facilitating the accessibility of transcription factors to its promoter through histone covalent modifications. Finally, zebrafish models of psoriasis have shown that a H2O2/NF-κB/Duox1 positive feedback inflammatory loop operates in this chronic inflammatory disorder and that pharmacological inhibition of Duox1, but not of downstream mediators, inhibits inflammation and restores epithelial homeostasis. Therefore, these results have pointed out DUOX1 and H2O2 as therapeutic targets for the treatment of skin inflammatory disorders, such as psoriasis.


Asunto(s)
Peróxido de Hidrógeno/metabolismo , Inflamación/inmunología , Neutrófilos/inmunología , Psoriasis/inmunología , Pez Cebra/inmunología , Animales , Oxidasas Duales/genética , Oxidasas Duales/metabolismo , Proteínas de Peces/genética , Proteínas de Peces/metabolismo , Humanos , Interleucina-8/metabolismo , FN-kappa B/genética , FN-kappa B/metabolismo , Cicatrización de Heridas
13.
Pediatr. aten. prim ; 21(82): 169-172, abr.-jun. 2019. ilus
Artículo en Español | IBECS | ID: ibc-184593

RESUMEN

La pitiriasis liquenoide es una entidad inflamatoria benigna de etiología aún desconocida. Existen dos subtipos dentro de esta entidad, la forma aguda (pitiriasis liquenoide varioliforme aguda) y la forma crónica (pitiriasis liquenoide crónica). Ambas son comunes en niños y adultos jóvenes. Describimos un caso de pitiriasis liquenoide aguda y discutimos su presentación clínica, diagnóstico y tratamiento: un escolar de 8 años que presenta un brote agudo de exantema papular pruriginoso con lesiones de distribución centrípeta, las cuales no variaron durante 3 semanas, aparecieron nuevas lesiones durante dicho periodo. La biopsia de las lesiones confirmó el diagnóstico de pitiriasis liquenoide. Tras completar el tratamiento con macrólidos y corticoide tópico se produjo remisión de las lesiones. La pitiriasis liquenoide aguda es una entidad poco frecuente que supone un reto diagnóstico para el pediatra. Su diagnóstico se basa en la sospecha clínica y la confirmación histopatológica. No tiene un tratamiento específico


Pityriasis lichenoides is a benign inflammatory disease of unknown etiology. There are two types of this entity: an acute form (pityriasis lichenoides et varioliformis acuta) and a chronic one (pityriasis lichenoides chronica). Both are common in children and young adults. We describe a case of pityriasis lichenoides, discuss its clinical presentation, diagnosis and treatment. An eight-year-old child who presented erythematous papular lesions in centripetal distribution, these lesions didn't improve in 3 weeks, and new lesions appeared in that period. The biopsy of the lesions confirmed pityriasis lichenoid. After antibiotic and corticosteroid treatment all lesions disappeared. Pityriasis lichenoides acute is a rare design that represents a diagnostic and therapeutic challenge to the physician. The diagnosis of this condition is suspected clinically and confirmed by histology. It does not have specific treatment


Asunto(s)
Humanos , Masculino , Niño , Pitiriasis Liquenoide/diagnóstico , Varicela/diagnóstico , Corticoesteroides/uso terapéutico , Antibacterianos/uso terapéutico , Metotrexato/uso terapéutico , Resultado del Tratamiento
18.
Am J Dermatopathol ; 38(8): 623-7, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27391452

RESUMEN

Primary cutaneous signet-ring cell carcinoma is a rare and aggressive neoplasm which diffusely involves dermis and subcutis of the eyelid or axillae. Neoplastic cells show a signet-ring cell or histiocytoid morphology in variable number, and can be found intermingled among collagen bundles, sparing the epidermis. This neoplasm typically appears in the eyelids of elderly men, in the form of a painless infiltration and swelling but with no other specific clinical feature, and frequently causes diagnostic retardation and worse prognosis. Frequent involvement of both eyelids of the same eye has given it the name of monocle tumor. Only 29 cases have been described in English literature to date, of which 7 developed metastases, mainly on regional lymph nodes. The authors present a case of involvement of contralateral eyelid, which has only been described previously in 2 cases. The immunohistochemical profile of the involvement in the contralateral eye, and the absence of other metastasis, suggest that it is locally spread from the initial lesion. However the possibility of being a second primary tumor or metastasis cannot be readily ruled out.


Asunto(s)
Carcinoma de Células en Anillo de Sello/patología , Neoplasias de los Párpados/patología , Histiocitos/patología , Neoplasias Cutáneas/patología , Anciano , Biomarcadores de Tumor/análisis , Biopsia , Carcinoma de Células en Anillo de Sello/química , Carcinoma de Células en Anillo de Sello/terapia , Neoplasias de los Párpados/química , Neoplasias de los Párpados/terapia , Histiocitos/química , Humanos , Inmunohistoquímica , Masculino , Procedimientos Quirúrgicos Oftalmológicos , Radioterapia Adyuvante , Neoplasias Cutáneas/química , Neoplasias Cutáneas/terapia , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...